NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $1.22 +0.02 (+1.67%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends Get Bright Minds Biosciences alerts: Email Address About Bright Minds Biosciences Stock (NASDAQ:DRUG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DRUG alerts:Sign Up Key Stats Today's Range$1.20▼$1.2450-Day Range$1.01▼$1.3652-Week Range$0.93▼$2.39Volume3,350 shsAverage Volume51,321 shsMarket Capitalization$5.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Read More… Don’t wait for FDA approval (Ad)Don’t let Wall Street fool you. AI is not the only hot sector in the market. Biotech is on fire as well.And I’ll tell you all about them in this video. Bright Minds Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bright Minds Biosciences.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.68% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 41.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.68% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 41.65%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.14 News SentimentBright Minds Biosciences has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bright Minds Biosciences this week, compared to 0 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DRUG Stock News HeadlinesBright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Decline in Short InterestSeptember 26 at 3:20 PM | americanbankingnews.comBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thSeptember 19, 2024 | globenewswire.comEx-Wall Street CEO reveals “Millionaire-Maker” SuperdrugScience Magazine called it the "breakthrough of the year"... With projections of 8,966% growth in the next four years.September 29, 2024 | Behind the Markets (Ad)Bright Minds Biosciences (NASDAQ:DRUG) versus Contineum Therapeutics (NASDAQ:CTNM) Head-To-Head ComparisonSeptember 19, 2024 | americanbankingnews.comBright Minds Biosciences launches Phase II trial of absence epilepsy treatmentSeptember 14, 2024 | msn.comBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic EncephalopathySeptember 12, 2024 | prnewswire.comBright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D EffortsAugust 16, 2024 | benzinga.comMedical journal retracts three articles related to MDMA for PTSDAugust 12, 2024 | msn.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $1.43 on January 1st, 2024. Since then, DRUG stock has decreased by 14.7% and is now trading at $1.22. View the best growth stocks for 2024 here. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) announced its earnings results on Wednesday, August, 14th. The company reported $0.04 earnings per share (EPS) for the quarter. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences shares reverse split on the morning of Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/28/2024Fiscal Year End9/30/2024Next Earnings (Estimated)1/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CUSIPN/A CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.55% Return on Assets-53.79% Debt Debt-to-Equity RatioN/A Current Ratio35.07 Quick Ratio35.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.94Miscellaneous Outstanding Shares4,434,000Free Float2,542,000Market Cap$5.41 million OptionableNot Optionable Beta1.54 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:DRUG) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.